What is PreciseDx?
PreciseDx operates at the intersection of advanced pathology and artificial intelligence, serving as the only cancer risk stratification company that provides patient-specific risk information through the analysis of morphology features. By transforming traditional diagnostic workflows, the company enables clinicians to move beyond binary results, offering nuanced, personalized treatment insights that significantly improve patient outcomes. Its market position is bolstered by deep integration with major diagnostic laboratories and healthcare systems, ensuring that its innovative methodologies are accessible to a broad spectrum of medical providers and patients seeking more accurate prognostic data.
How much funding has PreciseDx raised?
PreciseDx has raised a total of $42.5M across 3 funding rounds:
Series A
$10.8M
Series B
$20.7M
Other Financing Round
$11M
Series A (2022): $10.8M with participation from Merck GHI, Agile Technologies, and Mount Sinai Health System
Series B (2024): $20.7M led by Quest Diagnostics, Labcorp, and Eventide Asset Management
Other Financing Round (2025): $11M supported by Quest Diagnostics Inc, Merck & Co, Labcorp, Philip Ventures, Eventide Asset Management, and GenHenn Capital
Key Investors in PreciseDx
Quest Diagnostics
A global leader in diagnostic information services, Quest Diagnostics leverages the world's largest database of clinical lab results to identify new avenues for disease treatment and healthcare management.
Labcorp
Labcorp is a premier laboratory services provider that delivers vital diagnostic insights to hospitals, pharmaceutical companies, and patients to facilitate confident, data-driven medical decisions.
Eventide Asset Management
An investment firm focused on values-based strategies, Eventide provides capital to companies that aim to create positive societal impact while achieving strong financial performance in the healthcare and technology sectors.
What's next for PreciseDx?
With this latest capital injection, PreciseDx is poised to transition into a new phase of commercial expansion and technological refinement. The strategic focus will likely center on deepening its clinical validation studies and broadening the application of its morphology-based risk models across various cancer types. As the company continues to align with major diagnostic partners, it is expected to enhance its data infrastructure, thereby increasing the scalability of its diagnostic services. This phase of development will be critical in establishing the company as the standard-bearer for personalized oncology, ultimately driving higher adoption rates among oncologists and health systems worldwide.
See full PreciseDx company page
